Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$1.79 USD
+0.09 (5.29%)
Updated Aug 5, 2025 03:57 PM ET
After-Market: $1.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Aprea Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
APRE 1.79 +0.09(5.29%)
Will APRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
Other News for APRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News
Aprea Therapeutics announces new preclinical data, update on APR-1051
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for ...
Aprea Therapeutics announces new preclinical data, update on APR-1051